BRPI1010297A2 - anticorpos biespecíficos trivalentes. - Google Patents

anticorpos biespecíficos trivalentes.

Info

Publication number
BRPI1010297A2
BRPI1010297A2 BRPI1010297A BRPI1010297A BRPI1010297A2 BR PI1010297 A2 BRPI1010297 A2 BR PI1010297A2 BR PI1010297 A BRPI1010297 A BR PI1010297A BR PI1010297 A BRPI1010297 A BR PI1010297A BR PI1010297 A2 BRPI1010297 A2 BR PI1010297A2
Authority
BR
Brazil
Prior art keywords
bispecific antibodies
trivalent bispecific
trivalent
antibodies
bispecific
Prior art date
Application number
BRPI1010297A
Other languages
English (en)
Inventor
Klein Christian
Hoffmann Eike
Moessner Ekkehard
Michael Schanzer Juergen
Umana Pablo
Croasdale Rebecca
Brinkmann Ulrich
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of BRPI1010297A2 publication Critical patent/BRPI1010297A2/pt
Publication of BRPI1010297B1 publication Critical patent/BRPI1010297B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1010297-3A 2009-04-07 2010-04-01 Anticorpo biespecífico trivalente e composição farmacêutica BRPI1010297B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09005108 2009-04-07
EP09005108.7 2009-04-07
PCT/EP2010/002122 WO2010115589A1 (en) 2009-04-07 2010-04-01 Trivalent, bispecific antibodies

Publications (2)

Publication Number Publication Date
BRPI1010297A2 true BRPI1010297A2 (pt) 2017-06-06
BRPI1010297B1 BRPI1010297B1 (pt) 2025-05-20

Family

ID=

Also Published As

Publication number Publication date
AU2010234031B2 (en) 2015-10-01
SG175077A1 (en) 2011-11-28
CY1116376T1 (el) 2017-02-08
KR20110130460A (ko) 2011-12-05
PT2417156E (pt) 2015-04-29
JP2014193181A (ja) 2014-10-09
CN102369214B (zh) 2019-04-12
CN102369214A (zh) 2012-03-07
JP5616428B2 (ja) 2014-10-29
US9890204B2 (en) 2018-02-13
DK2417156T3 (en) 2015-03-02
EP2417156A1 (en) 2012-02-15
US20130022601A1 (en) 2013-01-24
US20200062826A1 (en) 2020-02-27
US20100256340A1 (en) 2010-10-07
CA2757931C (en) 2019-03-26
JP2012522527A (ja) 2012-09-27
IL214884A0 (en) 2011-11-30
AU2010234031A8 (en) 2012-06-28
SI2417156T1 (sl) 2015-06-30
HRP20150444T1 (hr) 2015-05-22
MX2011010168A (es) 2011-10-11
WO2010115589A1 (en) 2010-10-14
CA2757931A1 (en) 2010-10-14
US20180282399A1 (en) 2018-10-04
WO2010115589A8 (en) 2011-10-27
PL2417156T3 (pl) 2015-07-31
KR101456326B1 (ko) 2014-11-12
AU2010234031A1 (en) 2011-09-08
EP2417156B1 (en) 2015-02-11
TW201039850A (en) 2010-11-16
AR076193A1 (es) 2011-05-26
IL214884A (en) 2015-09-24
ES2537100T3 (es) 2015-06-02
US11993642B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
BRPI1014474A2 (pt) anticorpos biespecíficos anti-erbb-1/anti-c-met.
IL214884A0 (en) Trivalent, bispecific antibodies
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI1012589A2 (pt) anticorpos bi-específicos anti-erbb-3/anti-c-met
PT2406284T (pt) Anticorpos anti-bcma
BR112012002226A2 (pt) anticorpos muc1.
DK2521736T3 (da) Humaniserede antistoffer
SMT201700083B (it) Anticorpi monoclonali
BRPI1011005A2 (pt) anticorpos anti-epcam
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
DK2443154T3 (da) Bispecifikke antigenbindingsproteiner
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
CR20170001A (es) Anticuerpos anti factor d humanizados
DK2225280T3 (da) Bivalente, bispecifikke antistoffer
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
HUE042898T2 (hu) Antitestek, amelyek kötnek CSF1R-t
IL217919A0 (en) Humanized anti-cdcp1 antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
DK2651436T3 (da) Mycobakterie antigen sammensætning.
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
CO6791565A2 (es) Anticuerpos anti-notch1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.